

TMH 4/30/02 6395-57049

PATENT

KLARQUIST SPARKMAN, LLP  
16th Floor World Trade Center  
121 S.W. Salmon Street  
Portland, Oregon 97204 U.S.A.  
503-226-7391  
(FAX 503-228-9446)

**REQUEST FOR CORRECTED FILING RECEIPT**  
**(TOTAL PAGES TRANSMITTED: 3)**

TO: Carolyn

CUSTOMER SERVICE CENTER, Art Group 1600

FAX NO.: 703-308-4407

RE: APPLICATION NO: 09/763,397

INVENTORS: Lal *et al.*

ATTY. REF.: 6395-57049

FILED: February 16, 2001

TITLE: RECOMBINANT MULTIVALENT MALARIAL VACCINE AGAINST  
PLASMODIUM FALCIPARUM

OFFICIAL

ART UNIT: 1645

FAX RECEIVED  
APR 30 2002  
GROUP 1600  
RECEIVED  
TECH CENTER 1600/22230  
02 APR 30 PM 1:50

Assistant Commissioner for Patents  
Washington, D.C. 20231

An error appears on the official Filing Receipt issued for the above-identified patent application. In particular, a U.S. provisional application has been omitted from the priority data listed on the official Filing Receipt.

Attached hereto is a copy of the official Filing Receipt with the requested correction shown thereon. Also attached is a copy of the cover page of the published PCT application, showing the priority claim.

Please correct the identified error and issue a corrected official Filing Receipt.

I hereby certify that this paper and the associated documents are being facsimile transmitted to the Patent & Trademark Office on the date shown below.

Tanya M. Harding, Ph.D.  
Registration No. 42,630

April 30, 2002  
Date

cc: Docketing

PREVIOUSLY DOCKETED



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/763,397	02/16/2001	1645	860	6395-57049	5	12	1

CONFIRMATION NO. 4907

24197  
KLARQUIST SPARKMAN, LLP  
121 SW SALMON STREET  
SUITE 1600  
PORTLAND, OR 97204

## FILING RECEIPT



\*OC000000007018618\*

Date Mailed: 11/05/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Altat A. Lal, Atlanta, GA;  
Ya Ping Shi, Atlanta, GA;  
Sayed E. Hasnain, New Dehli, INDIA;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/18869 08/19/1999

AND CLAIMS THE BENEFIT OF US 60/097,703 Filed 08/21/98

## Foreign Applications

If Required, Foreign Filing License Granted 11/02/2001

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

## Title

Recombinant multivalent malarial vaccine against plasmodium falciparum

## Preliminary Class

424

CORRECTED  
VERSION\*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12N 15/30, 15/62, C07K 14/445, 16/20, A61K 39/015, A61P 33/06, G01N 33/569</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/11179</b>  <b>(43) International Publication Date:</b> <b>2 March 2000 (02.03.00)</b>
<b>(21) International Application Number:</b> <b>PCT/US99/18869</b>  <b>(22) International Filing Date:</b> <b>19 August 1999 (19.08.99)</b>  <b>(30) Priority Data:</b> <b>60/097,703</b> <b>21 August 1998 (21.08.98)</b> <b>US</b>  <b>(71) Applicants (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Centers for Disease Control, Technology Transfer Office, Executive Park, Building 4, Suite 1103, Atlanta, GA 30329 (US). NATIONAL INSTITUTE OF IMMUNOLOGY [IN/IN]; Department of Biotechnology, C.G.O. Complex, New Delhi 110 003 (IN).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAL, Altaf, A. [IN/US]; 2070 Asgard Court, Atlanta, GA 30345 (US). SHI, Ya, Ping [CN/US]; 2070 Asgard Court, Atlanta, GA 30345 (US). HASNAIN, Seyed, E. [IN/IN]; H-8, NII Campus, Aruna Asif Ali Marg, New Delhi 110 067 (IN).	<b>(74) Agents:</b> MCDONALD, John, K. et al.; Jones & Askew, LLP, 2400 Monarch Tower, 3424 Peachtree Road, Atlanta, GA 30326 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> RECOMBINANT MULTIVALENT MALARIAL VACCINE AGAINST <i>PLASMODIUM FALCIPARUM</i>  <b>(57) Abstract</b>  <p>A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of the parasite <i>Plasmodium falciparum</i>. The protein is useful as a reagent and, when combined with a pharmaceutically-acceptable vehicle or carrier, is useful as a vaccine against the malarial parasite <i>Plasmodium falciparum</i>. A genetic construct used to produce this recombinant protein vaccine is also described. In addition, antibodies to this recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite <i>Plasmodium falciparum</i>.</p>		